Role of quercetin as a promising antiviral, therapeutic and immunomodulatory mediator against dengue virus induced robust infection in in-vivo Balb/C mice model

IF 5.9 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2025-06-05 Epub Date: 2025-03-20 DOI:10.1016/j.ejmech.2025.117536
Saikat Mukherjee, Anusri Tripathi
{"title":"Role of quercetin as a promising antiviral, therapeutic and immunomodulatory mediator against dengue virus induced robust infection in in-vivo Balb/C mice model","authors":"Saikat Mukherjee,&nbsp;Anusri Tripathi","doi":"10.1016/j.ejmech.2025.117536","DOIUrl":null,"url":null,"abstract":"<div><div>Currently, there are no clinically approved antiviral agents against dengue-virus (DENV). This study aimed to determine the prophylactic, antiviral, and therapeutic potential of quercetin by its pre-treatment, co-treatment, and post-treatment [24, 48, and 72 h-post-infection (HPI)] of DENV-infected Balb/C mice through both oral and intraperitoneal (I.P) route, respectively. 80 mg/kg/day and 16 mg/kg/day of quercetin were non-toxic for oral and I.P administration, respectively. I.P. was found to be more effective than oral administration which significantly reduced DENV copy-number in co-treatment group (from day 1, <em>p</em> &lt; 0.01); post-treatment (24hpi),and pretreatment groups (day 3 onwards, <em>p</em> &lt; 0.05). Molecular-docking experiments indicated quercetin could act as a double-edged sword by strongly interacting with DENV envelope-glycoprotein (−8.1 kcal/mol) and NS5-RdRp domain (−8.0 kcal/mol), which are crucial for viral-attachment and replication. MD-simulation of docked complexes indicated their stability defined by low RMSD, RMSF, and stable H-bond with active-site residues. Significant reduction (<em>p</em> &lt; 0.001) in TNF-α, IL-6, ROS-production, and vascular leakage was observed among pre-, co-, and post-treatment (24 and 48 HPI) groups with promising hepatic and renal-protective effects. Pharmacological and functional-molecular interaction networks indicate a significant effect of quercetin on vascular integrity byVEGF-KDR signaling pathway (via PI3K-Akt and Ras signalling), oxygen homeostasis through HIF-1 signalling, and the anti-inflammatory response via PI3K-Akt, IL-6 and its receptor signalling (PPI enrichment P = 3.19e-10).Thus, it can be concluded that I.P. co- and post-treatment (24hpi) of quercetin to DENV-infected mice could effectively reduce viral-titer, pro-inflammatory cytokines, ROS-response, and vascular permeability. Taken together this demonstrates quercetin as an important antiviral candidate against dengue.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"290 ","pages":"Article 117536"},"PeriodicalIF":5.9000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425003010","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, there are no clinically approved antiviral agents against dengue-virus (DENV). This study aimed to determine the prophylactic, antiviral, and therapeutic potential of quercetin by its pre-treatment, co-treatment, and post-treatment [24, 48, and 72 h-post-infection (HPI)] of DENV-infected Balb/C mice through both oral and intraperitoneal (I.P) route, respectively. 80 mg/kg/day and 16 mg/kg/day of quercetin were non-toxic for oral and I.P administration, respectively. I.P. was found to be more effective than oral administration which significantly reduced DENV copy-number in co-treatment group (from day 1, p < 0.01); post-treatment (24hpi),and pretreatment groups (day 3 onwards, p < 0.05). Molecular-docking experiments indicated quercetin could act as a double-edged sword by strongly interacting with DENV envelope-glycoprotein (−8.1 kcal/mol) and NS5-RdRp domain (−8.0 kcal/mol), which are crucial for viral-attachment and replication. MD-simulation of docked complexes indicated their stability defined by low RMSD, RMSF, and stable H-bond with active-site residues. Significant reduction (p < 0.001) in TNF-α, IL-6, ROS-production, and vascular leakage was observed among pre-, co-, and post-treatment (24 and 48 HPI) groups with promising hepatic and renal-protective effects. Pharmacological and functional-molecular interaction networks indicate a significant effect of quercetin on vascular integrity byVEGF-KDR signaling pathway (via PI3K-Akt and Ras signalling), oxygen homeostasis through HIF-1 signalling, and the anti-inflammatory response via PI3K-Akt, IL-6 and its receptor signalling (PPI enrichment P = 3.19e-10).Thus, it can be concluded that I.P. co- and post-treatment (24hpi) of quercetin to DENV-infected mice could effectively reduce viral-titer, pro-inflammatory cytokines, ROS-response, and vascular permeability. Taken together this demonstrates quercetin as an important antiviral candidate against dengue.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
槲皮素作为一种有前景的抗病毒、治疗和免疫调节介质在体外抗登革热病毒诱导的强感染小鼠模型中的作用
目前,尚无临床批准的针对登革热病毒(DENV)的抗病毒药物。本研究旨在通过口服和腹腔灌胃分别对感染denv的Balb/C小鼠进行预处理、共处理和后处理[感染后24、48和72小时(HPI)],以确定槲皮素的预防、抗病毒和治疗潜力。槲皮素80mg/kg/d口服和16mg/kg/d内服均无毒。联合治疗组的DENV拷贝数显著降低(从第1天开始,p<0.01), I.P.比口服给药更有效;治疗后(24hpi)和预处理组(第3天起,p < 0.05)。分子对接实验表明,槲皮素与DENV包膜糖蛋白(-8.1 kcal/mol)和NS5-RdRp结构域(-8.0 kcal/mol)具有很强的相互作用,是一把双刃剑,对病毒的附着和复制至关重要。md模拟表明,对接配合物的稳定性由低RMSD、RMSF和具有活性位点残基的稳定氢键定义。在治疗前、联合治疗和治疗后(24和48 HPI)组中,TNF-α、IL-6、ros生成和血管渗漏均显著降低(p<0.001),具有良好的肝脏和肾脏保护作用。药理和功能分子相互作用网络表明,槲皮素通过vegf - kdr信号通路(通过PI3K-Akt和Ras信号通路),通过HIF-1信号通路维持氧稳态,通过PI3K-Akt、IL-6及其受体信号通路影响血管完整性(PPI富集P = 3.19e-10)。由此可见,槲皮素对denv感染小鼠的I.P.共处理和后处理(24hpi)可有效降低病毒滴度、促炎因子、ros反应和血管通透性。综上所述,槲皮素是一种重要的登革热抗病毒候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Discovery of novel covalent agonists for p53 Y220C through synergistic strategy combining covalent binding and scaffold hopping Novel methoxyquinazoline sulfonamide derivatives as angiogenesis inhibitors and radiosensitizers Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity Porphyrins modified fibroblast activation protein inhibitor for enhanced cancer radionuclide therapy Novel design of interleukin-2 derivatives with reversed pH and potent antitumor activity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1